How do you figure it would be faster and less costly. Some figures please on the cost of long dog studies. Then consider the FDA was going to knock it back anyway. The cheapest and least costly path IMO would have been to avoid the FDA, who have a dismal record approving HD drugs, and going directly to a trial outside the USA, as Roche are doing with their HD drug.
Ann: Prana provides regulatory update for PBT2-PBT.AX, page-55
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $4.579K | 1.526M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 749591 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 133062022 | 26 |
View Market Depth
| Last trade - 14.03pm 13/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |